Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ARAF | P10398 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690167 | 0.85 | MAPT (0.38) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1303731 | 0.84 | CFTR (0.49) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1404705 | 0.83 | RARG (0.38) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1600588 | 0.83 | HSD17B10 (0.44) | MAPTALDH1A1HPGDCFTRRARG | |
| SCHEMBL16158049 | 0.82 | CA12 (0.44) | MAPTSMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL9290267 | 0.82 | CNR1 (0.45) | ALDH1A1MAPK14 | |
| SCHEMBL19047476 | 0.82 | MAPK14 (0.39) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL28664475 | 0.80 | MAPT (0.38) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL19047477 | 0.79 | MAPT (0.36) | MAPTTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1404537 | 0.79 | HTT (0.43) | SMN1; SMN2ALDH1A1MAPK14SRCSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | claimed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3394059-B1 | 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | CHIESI FARM SPA (IT) | 2020-11-25 | — | — | EP | disclosed |
| EP-3394059-B1 | 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | CHIESI FARM SPA (IT) | 2020-11-25 | — | — | EP | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| EP-3394059-A1 | 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2018-10-31 | — | — | EP | disclosed |
| US-10100050-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-10-16 | — | — | US | disclosed |
| US-20180044288-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9790174-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| US-6743788-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-01 | — | — | US | disclosed |
| EP-1395561-A1 | CARBAMATE AND OXAMIDE COMPOUNDS AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030092702-A1 | Novel carbamate and oxamide compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | US | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002096876-A1 | CARBAMATE AND OXAMIDE COMPOUNDS AS INHIBITORS OF CYTOKINE PRODUCTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044288-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPT 3802/4885TP53 2887/4885SMN1; SMN2 4352/4885 |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | MAPT 2764/4885TP53 1509/4885SMN1; SMN2 3469/4885 |
| US-20030092702-A1 | Novel carbamate and oxamide compounds | IFNG, CXCR1, ARG1 | MAPT 4037/4885TP53 3172/4885SMN1; SMN2 4144/4885 |
| US-10100050-B2 | Kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | MAPT 3130/4885TP53 3360/4885SMN1; SMN2 4129/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | MAPT 3802/4885TP53 2887/4885SMN1; SMN2 4352/4885 |
| US-20060235017-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1R1 | MAPT 4352/4885TP53 898/4885SMN1; SMN2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.